Availability (in Japan)
1-9
(In Japan at 00:05,
May 17, 2022 in JST)
Size
50 µg/50 µL
Data | |||||
---|---|---|---|---|---|
Clonality | Monoclonal | Clone | 107-1A4 | ||
Isotype (Immunized Animal) | Mouse IgG1 | ||||
Applications |
|
||||
Immunogen (Antigen) | LNCaP cell homogenate | ||||
Reactivity [Gene ID] | Human[2346] |
||||
Storage buffer | 1 mg/mL in PBS/1% BSA/0.1% ProClin 150 | ||||
Storage temp. | 4°C | Conjugate | Unlabeled | Manufacturer | MBL |
Alternative names | FOLH1, folate hydrolase (prostate-specific membrane antigen) 1 | ||||
Background | PSMA is a type II transmembrane protein expressed at high levels in prostate cancer and in tumor-associated neovasculature. PSMA is also known as a glutamate carboxypeptidase II (EC 3.4.17.21) that hydrolyzes the neuropeptide, N-acetyl-L-aspartyl-L-glutamate, releasing glutamate, the dominant excitatory neurotransmitter/neuromodulator of the mammalian central nervous system. The ability of PSMA to liberate g-glutamate may allow the removal of glutamate residues from dietary folates, which are unable to be transported into cells in their poly-g-glutamate form. Overexpression of PSMA in prostate cancer cells may represent an advantageous adaptation that allows the uptake of folates required for rapid division. The exopeptidase activity exhibited by PSMA and its high-level overexpression in prostate cancer cells make it a potential target for selective anticancer therapy and prodrug activation. |
||||
Related products | K0142-3 Anti-PSMA (Human) mAb K0142-4 Anti-PSMA (Human) mAb-FITC K0142-5 Anti-PSMA (Human) mAb-PE |
||||
References |
|
||||
Product category |
|